Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Myriad Genetics Inc (NQ: MYGN )

27.06 USD +0.03 (+0.11%)
Streaming Delayed Price Updated: 1:00 PM EDT, May 18, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Myriad Genetics Inc

< Previous 1 2 3 4 5 6 7 8 9
...
83 84 Next >
New Study from Leading University of Utah Radiation Oncologist Validates Ability of Myriad Genetics’ Prolaris® test to Guide Treatment for Prostate Cancer
Results from second study cite Prolaris® as most clinically significant prognostic parameter of outcomes at time of diagnosis, identifying men who need aggressive hormonal treatment and those who can... 
From GlobeNewswire News Releases
Myriad Genetics to Participate in Multiple Upcoming Health and Technology Conferences
From GlobeNewswire News Releases
GeneSight Psychotropic Test’s Combinatorial Approach Proves Better than Single-Gene Testing at Predicting Patient Outcomes and Medication Blood Levels
From GlobeNewswire News Releases
The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ... 
Tags Earnings IPOs ASRT
From Benzinga
Myriad Genetics Launches New Vectra® Cardiovascular Risk Assessment for Patients with Rheumatoid Arthritis
From GlobeNewswire News Releases
First Week of MYGN August 20th Options Trading
Investors in Myriad Genetics, Inc. (MYGN) saw new options become available this week, for the August 20th expiration.. 
Tags Stocks
From Market News Video
Myriad Genetics, Inc. (NASDAQ:MYGN) Investor Notice: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 01/25/2021 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Myriad Genetics, Inc. 
From SBWire - Latest Press Releases
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Myriad Genetics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of... 
From PR Newswire
Myriad Genetics Forms Strategic Partnership with Illumina in Oncology
From GlobeNewswire News Releases
The Daily Biotech Pulse: Aerpio Reviews Strategic Options, Hologic Goes Shopping
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ... 
Tags ORGO NEO MITO
From Benzinga
Myriad Genetics Provides Transformation Update, Pursues Strategic Alternatives for Autoimmune Business, Realigns International Operations
Focus on Women’s Health, Oncology, Mental Health to Improve Execution and Accelerate Growth 
From GlobeNewswire News Releases
Myriad Genetics CEO Paul J. Diaz to Present at 39th Annual J.P. Morgan Healthcare Conference
From GlobeNewswire News Releases
IBD Rating Upgrades: Myriad Genetics Flashes Improved Relative Price Strength
A Relative Strength Rating upgrade for Myriad Genetics shows improving technical performance. Will it continue? 
From Investor's Business Daily
New Study Provides Personalized Breast Cancer Risk Information for Women with ATM Gene Mutations
From GlobeNewswire News Releases
Myriad Genetics Getting Closer To Key Technical Measure
Myriad Genetics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating 
From Investor's Business Daily
IBD Rating Upgrades: Myriad Genetics Flashes Improved Technical Strength
Myriad Genetics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating 
From Investor's Business Daily
IPM Launches Innovative Program for Rheumatoid Arthritis
Integrated Prescription Management (IPM), a leading pharmacy benefits management (PBM) company, has signed a contract with Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and... 
From PR Newswire
Land This Deal Even Lower Than Director Phanstiel Did
There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on November 11, Myriad Genetics, Inc.'s Director, S.. 
Tags Stocks
From Market News Video
Suffering in Silence: Two-Thirds of Older Adults Say They Won’t Treat Their Depression
New nationwide poll shows 1 in 3 respondents age 65+ think they can just “snap out of it” 
From GlobeNewswire News Releases
Myriad Genetics Announces Global Expansion of Myriad myChoice® Tumor Testing in Europe and China
From GlobeNewswire News Releases
Burning Rock Announces In-Licensing of Myriad myChoice® Tumor Testing in China
From GlobeNewswire News Releases
Thursday 11/12 Insider Buying Report: MYGN, ARAY
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their... 
Tags Stocks
From Market News Video
New Data Show Importance of Vectra® Testing and Biomarkers in Predicting Risk for Cardiovascular Events in Patients with Rheumatoid Arthritis
From GlobeNewswire News Releases
Myriad Genetics Delivers 56% Sequential Increase in Quarterly Revenue; Test Volumes Reach 90% of Pre-COVID-19 Level at End of Quarter
From GlobeNewswire News Releases
The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions
Biotech stocks turned around with the broader market in the week ended Nov. 6, as investors warmed to the idea of a split Congress and a ... 
Tags PTE RDHL DARE
From Benzinga
Myriad Genetics to Announce Quarterly Financial Results on November 9, 2020
From GlobeNewswire News Releases
First Week of MYGN October 16th Options Trading
Investors in Myriad Genetics, Inc. (MYGN) saw new options become available this week, for the October 16th expiration.. 
Tags Stocks
From Market News Video
Myriad Genetics Files Fiscal Year 2020 Proxy Statement, Implements Corporate Governance Changes In Support of Stakeholder Interests
From GlobeNewswire News Releases
The MYGN Paradox: Analysts Bearish But Forecast 12.62% Gains
Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with Myriad Genetics, Inc. (MYGN).. 
Tags ETFs
From ETF Channel
Myriad Genetics and Sandstone Diagnostics Form Point-of-Care Blood Collection Partnership
Tags business/economy c:united/kingdom companies
From EIN Presswire
< Previous 1 2 3 4 5 6 7 8 9
...
83 84 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.